Every Form 4 that Ascendis Pharma A/S (ASND) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ASND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASND filings page.
Jean Jacques Bienaime, a director of Ascendis Pharma A/S (ASND), agreed to the cancellation of 9,160 warrants granted June 10, 2025, and was awarded a new warrant covering 9,160 underlying Ordinary Shares on April 14, 2026, as part of his board appointment. The cancelled warrant has an exercise price of 172.35 and expires June 10, 2035; it vests 25% on June 10, 2026, followed by 36 equal monthly installments. The new warrant has an exercise price of 249.84 and expires April 14, 2036. It vests 25% on April 14, 2027, followed by 36 equal monthly installments.
Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share. Following the exercise, 687 warrants remain outstanding, expiring on October 11, 2032, and no Rule 10b5-1 trading plan is reported.
Ascendis Pharma A/S (ASND) director Lars Holtug reported selling 236 Ordinary Shares on September 2, 2026 in an open-market or private transaction at $264.13 per share. After this sale, he directly holds 4,000 Ordinary Shares of Ascendis Pharma A/S.
No Rule 10b5-1 trading plan is reported for this transaction.
Ascendis Pharma A/S (ASND) director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On 2026-08-14 he purchased a total of 2,000 shares in two transactions at weighted average prices of $245.85 for 1,100 shares and $246.91 for 900 shares, with each price reflecting multiple trades within disclosed ranges. The Rule 10b5-1 checkbox was not marked, indicating these purchases were not reported as made under a trading plan.
Ascendis Pharma A/S EVP & Chief Financial Officer Scott Thomas Smith made an open-market purchase of 100 Ordinary Shares on June 2, 2026 at $219.00 per share.
Following this transaction, he directly holds 4,367 Ordinary Shares of Ascendis Pharma A/S.
Ascendis Pharma A/S director Jean Jacques Bienaime reported three open-market purchases of Ordinary Shares. On May 29, 2026, he bought a total of 500 shares at prices ranging from $222.30 to $223.76 per share. Following these transactions, he directly holds 900 Ordinary Shares of Ascendis Pharma, with no sales reported in this filing.
Ascendis Pharma A/S Executive Vice President and Chief Financial Officer Scott Thomas Smith executed an open-market purchase of 250 Ordinary Shares on May 29, 2026 at $223.32 per share. Following this transaction, his directly held position increased to 4,267 Ordinary Shares.
Ascendis Pharma A/S director Jean Jacques Bienaimé reported open-market purchases of the company’s Ordinary Shares. On May 26, 2026, he bought a total of 400 shares in two transactions, at weighted average prices of $236.235 and $239.3675 per share, executed across multiple trades within narrow intraday price ranges.
Ascendis Pharma A/S officer Flemming Steen Jensen sold all his reported holdings in a single transaction. On May 11, 2026, he executed an open-market sale of 19,460 Ordinary Shares at an average price of $238.4903 per share, leaving 0 shares directly owned after the trade.